2020 American Society of Hematology (ASH) Annual Meeting
Oral Presentation Title: A Phase I Study of Lintuzumab Ac225 in Combination with CLAG-M Chemotherapy in Relapsed/Refractory AML
Publication Number: 165
Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Advances in immunotherapeutics for management of AML
Session Date: Saturday, December 5, 2020
Presentation Time: 12:00 PM PT / 3:00 PM ET
Oral Presentation Title: Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered
Publication Number: 193
Session Name: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities
Session Date: Saturday, December 5, 2020
Presentation Time: 1:00 PM PT / 4:00 PM ET
Poster Title: Lintuzumab-225Ac in Combination with Venetoclax in Relapsed/Refractory AML: Early Results of a Phase I/II Study
Publication Number: 2875
Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Session Date: Monday, December 7, 2020
Presentation Time: 7:00 AM – 3:30 PM PT / 10:00 AM – 6:30 PM ET